CN1562004A - Preparation containing methimazole and its preparing method - Google Patents
Preparation containing methimazole and its preparing method Download PDFInfo
- Publication number
- CN1562004A CN1562004A CN 200410022207 CN200410022207A CN1562004A CN 1562004 A CN1562004 A CN 1562004A CN 200410022207 CN200410022207 CN 200410022207 CN 200410022207 A CN200410022207 A CN 200410022207A CN 1562004 A CN1562004 A CN 1562004A
- Authority
- CN
- China
- Prior art keywords
- thiamazole
- gram
- grams
- mix homogeneously
- lactose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
A slowly-releasing thiazmazole tablet for treating thyroidism is disclosed. It is prepared by unique slow-releasing technique, that is using high molecular material to wrap the medicine.
Description
Technical field: the present invention relates to a kind of preparation that contains thiamazole and preparation method thereof,, belong to technical field of medicaments especially for hyperthyroid chemical medicine preparation of treatment and preparation method thereof.
Technical background: hyperthyroidism is called for short " hyperthyroidism ", is because thyroid function increases, and the thyroxine of supersecretion causes the oxidizing process quickening, one group of common endocrinopathy that metabolic rate increases.Clinically with the big companion's hyperthyroidism of diffuse goiter and the big companion's hyperthyroidism of nodular goiter for seeing more, account for hyperthyroidism patient's about 90%.It mainly shows as nerve excitability and increases, and is the hypermetabolism state.Thyroid anthorisma cardinal symptom: To Be Protected from Heat, hyperhidrosis, low grade fever, fatigue and weak, lose weight, and often with exophthalmos, primary disease is more common in the women, and men and women's ratio is about 1: 4-6, with 20～40 years old the young and the middle aged for seeing more.The thiamazole sheet has the synthetic effect of the thyroxin of inhibition.It is the representative medicine of imidazoles antithyroid drug.Be used for various types of hyperthyroidisms, comprise Graves disease (accompany autoimmune function disorder, thyroid anthorisma, expophthalmos can be arranged), thyroid adenoma, nodular goiter and thyroid carcinoma institute causer.But it is big that the ordinary tablet half-life is lacked (about 3 hours) dose, takes often, and the patient takes inconvenience, and blood drug level is not steady, and there is safety problem in life-time service.In the prior art thiamazole is prepared into tablet, the problem that it exists is: mouthfeel is bad, and the patient is difficult to accept; For gastric mucosa stimulation is arranged; Easily, influence the absorption of effective ingredient by stomach acids destroy.
Summary of the invention: the objective of the invention is to, a kind of preparation that contains thiamazole and preparation method thereof is provided, the medicine that this method obtains is a kind of methimazole preparation, because its processing technology is relatively unique, with water-insoluble macromolecular material ethyl cellulose medicine is wrapped up, with macromolecular material hydroxypropyl emthylcellulose (K
100M) be skeleton, again with addition combination inside and outside the magnesium stearate, make thiamazole soluble in water need only sooner or later respectively obey 1 every day and can keep stable blood concentration from becoming for one day 3 times, taking convenience, mouthfeel is good and also higher than the bioavailability of conventional tablet, can also reduce the toxic and side effects of medicine, not stimulate for gastric mucosa; Being difficult for by stomach acids destroy, is better antithyroid drug medication.The present invention constitutes like this: contain the preparation of thiamazole, be prepared into slow releasing tablet, drop pill, capsule, slow releasing capsule, granule, spray agent by thiamazole and adjuvant assembly.The thiamazole slow releasing tablet is formed by following material, and per thousand are by weight ratio: thiamazole 5-30 gram, ethyl cellulose 5-30 gram, hydroxypropyl emthylcellulose (K
100M) 20-70 restrains, water soluble starch 10-30 restrains, lactose 10-30 restrains, magnesium stearate 10-30 restrains, calcium carbonate 5-35 gram.Per thousand slice prescriptions and the ratio of slow releasing tablet are: thiamazole 10 grams, ethyl cellulose 10 grams, hydroxypropyl emthylcellulose (K
100M) 20 grams, water soluble starch 20 gram, lactose 20 grams, magnesium stearate 20 grams, calcium carbonate 30 grams.The preparation method of thiamazole slow releasing tablet: according to given ratio, with thiamazole, ethyl cellulose, hydroxypropyl emthylcellulose (K
100M), magnesium stearate, that calcium carbonate was pulverized 100 mesh sieves respectively was standby, it is standby as coating solution 1. ethyl cellulose to be made into 20% solution with ethanol, 2. with thiamazole and hydroxypropyl emthylcellulose (K
100M) by equivalent incremental method mix homogeneously, with an amount of coating solution with it parcel after, wrap up with remaining coating solution again with behind magnesium stearate, the part calcium carbonate mix homogeneously, mix homogeneously such as last and calcium carbonate, water soluble starch, lactose, 20 mesh sieves are granulated, oven dry, 18 mesh sieve granulate, add tabletting behind the 2% magnesium stearate mix homogeneously again.Drop pill is formed by following material, by weight ratio: thiamazole 5-30 gram, water soluble starch 10-30 gram, lactose 10-30 gram; Substrate comprises a kind of of stearic acid or PEG6000 or PEG4000, and by medicated powder: substrate=1: 1-2 makes.Being produced as follows of drop pill: thiamazole 5-30 gram, water soluble starch 10-30 gram, lactose 10-30 gram was pulverized 100 mesh sieves and is selected mix homogeneously stand-by; Press medicated powder: substrate=1: 1-2, with following substrate: after stearic acid or PEG6000 or the PEG4000 fusion, it is even to add medicament mixed, 60-70 ℃ of insulation dripped/minute added in liquid paraffin or the methyl-silicone oil with 40-70, collects drop pill, draw liquid coolant with filter paper, make drop pill.Capsule is with thiamazole 5-30 gram, water soluble starch 10-30 gram, and lactose 10-30 restrains mix homogeneously, adds 10-60 gram beta-schardinger dextrin-, and filled capsules is made.Granule is with thiamazole 5-30 gram, water soluble starch 10-30 gram, and lactose 10-30 gram is made soft material with the ethanol of 40-90% concentration, makes granule with 20 mesh sieves, 60-80 ℃ of oven dry, granulate makes.Spray is that thiamazole 5-30 is restrained, water soluble starch 10-30 gram, lactose 10-30 gram mix homogeneously is stand-by, adds 10-30% tween 80 alcoholic solution 10-100ml, adds 1,2-propylene glycol 50-300ml, mixing, ethanol is settled to 40--1000ml, is sub-packed in the aerosol pressure bottle by 10-100ml (specification), in every bottle, be pressed into dichlorodifluoromethane 1-10 gram behind the gland, make.Slow releasing capsule is with thiamazole 10 grams, ethyl cellulose 10 grams, hydroxypropyl emthylcellulose (K
100M) 20 grams, water soluble starch 20 gram, lactose 10 grams, magnesium stearate 20 grams, that calcium carbonate 30 gram pulverize separately are crossed 100 mesh sieves is standby, 1. ethyl cellulose is made into 20% solution for standby with ethanol, 2. with thiamazole and hydroxypropyl emthylcellulose (K
100M) by equivalent incremental method mix homogeneously, with an amount of coating solution with it parcel after, wrap up with remaining coating solution again with behind the magnesium stearate mix homogeneously, last and calcium carbonate, water soluble starch, lactose mix homogeneously, the granulation of 20 mesh sieves, oven dry, 18 mesh sieve granulate, after adding 2% magnesium stearate mix homogeneously again, divide the capsule of packing into, make.
Because thiamazole is water-soluble, so consider to make insoluble matrix tablet, adopt ethyl cellulose as blocker, be porogen with the lactose, regulate rate of releasing drug.
Compared with prior art: this medicine has the synthetic effect of the thyroxin of inhibition.It is the representative medicine of imidazoles antithyroid drug.Be used for various types of hyperthyroidisms, comprise Graves disease (accompany autoimmune function disorder, thyroid anthorisma, expophthalmos can be arranged), thyroid adenoma, nodular goiter and thyroid carcinoma institute causer.The oral back of this product is by the fast absorption of gastrointestinal tract, and absorbance is about 70%-80%, is distributed widely in whole body, but the Thyreoidine that concentrates, the protein bound of in blood, getting along well, T1/2 is about 3 hours.Thiamazole and metabolite 75%-80% are through homaluria.Easily also can be through galactopoiesis by Placenta Hominis.Every of conventional tablet contains thiamazole 5mg, and adult's beginning consumption is 30mg every day, can be adjusted to 15-40mg by state of an illness weight, maximum consumption 60mg on the one, and gradation is oral; After the state of an illness control, decrement gradually, every order maintenance dose need be between 5-15mg by the state of an illness, is generally the course of treatment 12-18 month.Based on the big characteristics of conventional tablet each dose every day, can reduce medicining times and consumption, instructions of taking after making slow releasing tablet: oral, one time 1,1 time on the one.
Preparation of the present invention can add adjuvant and make drop pill, capsule, slow releasing capsule, spray, clinical acceptable forms such as granule; Described adjuvant comprises disintegrating agent, correctives, coloring agent, binding agent, lubricant, substrate etc.
Compared with prior art: owing to use the drop pill technology to increase stability of drug, the bioavailability height, few side effects, the drug effect performance is rapidly.Use capsule technique can cover the bitterness of medicine own, reduce the zest of medicine, increased stability of drug, in gastrointestinal tract, disperse soon, good absorbing, the bioavailability height is particularly suitable for the hyperthyroidism crisis treatment.Used slow release method, it is steady that this medicine has medication blood drug level, few side effects, and the length of holding time reduces the number of times of taking medicine.
Experimental example 1: thiamazole slow releasing tablet best prescription orthogonal design
Table 1 orthogonal design factor level table
| Factor | Hydroxypropyl emthylcellulose g | Water soluble starch g | Ethyl cellulose % | Lactose g |
| Level 1 level 2 levels 3 | ????20 ????40 ????60 | ????10 ????20 ????30 | ????10 ????20 ????30 | ??0 ??10 ??20 |
Table 2 thiamazole slow releasing tablet orthogonal design table
As can be known from the above table, key factor is the hydroxypropyl emthylcellulose (K that forms skeleton
100M) consumption.From 2,6,12 hours release data as can be known, preferred plan should be A
1B
2C
2D
2, promptly the consumption of hydroxypropyl emthylcellulose is 20 grams, and the consumption of water soluble starch is 20 grams, and the concentration of ethyl cellulose is 20% o'clock, and the release in vitro degree is ideal.
Experimental example 1: thiamazole slow releasing tablet animal pharmacokinetics test
By setting up the HPLC method of measuring thiamazole concentration in the dog plasma, with the thiamazole ordinary tablet is standard control, relative bioavailability with area-method estimation thiamazole slow releasing tablet is 113.2%, the bioavailability of slow releasing tablet is higher than ordinary tablet, after giving Canis familiaris L. 10mg thiamazole slow releasing tablet, the terminal half-life of estimation is 9.20 ± 1.51 hours, and peak time and peak concentration were respectively 4.9 ± 1.8 hours and 121.37 ± 27.66ng/ml; , MRT is 11.72 ± 2.13 hours, AUC is 1251.3 ± 294.1ng.h/ml.After giving Canis familiaris L. 10mg thiamazole ordinary tablet, the terminal half-life of estimation is 3.10 ± 1.09 hours, and peak time and peak concentration were respectively 1.7 ± 0.3 hours and 261.31 ± 11.23ng/ml; , MRT is 5.42 ± 0.67 hours, AUC is 987.32 ± 265.6ng.h/ml.Show slow releasing tablet t1/2, MRT significantly greater than ordinary tablet (P＜0.05) through the t check analysis, peak time prolongs (P＜0.1), and peak concentration significantly is lower than ordinary tablet (P＜0.01), and two preparation AUC do not have significant difference (P＞0.2).Illustrate that slow releasing tablet has slow release effect, but the degree of absorption there was no significant difference.
Experimental example 2: thiamazole capsule clinical trial
First group 40 examples are obeyed 1 of thiamazole capsule every day; Common 2 of second group 20 example usefulness every days thiamazoles.In 4～8 weeks of the course of treatment, first group clinical symptoms is all alleviated, heart rate＜90 time/minute, serum T
3, T
4Reduce to normally, the second group is all alleviated.Two groups the treatment after serum T
3, T
4All obviously descend than treatment is preceding with antithyroglobulin antibodies, antithyroid microgranule antibody, statistical procedures all has significant difference (P＜0.05～0.01=.
Experimental example 3: thiamazole drop pill, thiamazole granule and thiamazole spray be to rat T3, the influence of T4 and TSH value
Get rat and be divided into four groups at random, 1. thiamazole drop pill group 10mgkg
-1, 25; 2. thiamazole groups of grains 20mgkg
-1, 25; 3. thiamazole spray 20mgkg
-1, 25; 4. thiamazole ordinary tablet 2.7mgkg
-1The oral administration group,
5. blank group, in 7 weeks of successive administration thing, a gang A gets blood 5ml, and separation of serum is measured rat T3, T4 and TSH value.The results are shown in following table
| Group T3/molL -1????T4/mol·L -1??????TSH?mol·L -1 |
| Thiamazole drop pill 0.244 ± 0.142 **?0.364±0.531 **???0.762±0.203 *Thiamazole granule 0.132 ± 0.042 *??0.165±0.320 *???0.863±0.331 *Thiamazole spray 0.235 ± 0.253 *??1.453±0.784 *???0.349±0.223 *Blank group 0.893 ± 0.291 3.670 ± 0.125 0.885 ± 0.632 |
Annotate: compare * * P＜0.01 *＜0.05 with matched group
The result shows, compares with matched group, and thiamazole drop pill, thiamazole granule and thiamazole spray, to rat blood serum T3, T4 and TSH have remarkable inhibitory action, P＜0.05.
Concrete embodiment:
Embodiments of the invention 1: be with thiamazole 10 grams, ethyl cellulose 10 grams, hydroxypropyl emthylcellulose (K
100M) 20 grams, water soluble starch 20 gram, lactose 20 grams, magnesium stearate 20 grams, that calcium carbonate 30 gram pulverize separately are crossed 100 mesh sieves is standby.1. ethyl cellulose is made into 20% solution for standby with ethanol.2. with thiamazole and hydroxypropyl methyl fiber (K
100M) plain by equivalent incremental method mix homogeneously, with an amount of coating solution with it parcel after, again with magnesium stearate, wrap up with remaining coating solution behind the part calcium carbonate mix homogeneously, last and calcium carbonate, water soluble starch, lactose mix homogeneously, 20 mesh sieves are granulated, oven dry, 18 mesh sieve granulate, are pressed into the slow releasing tablet that specification is 10mg after adding 2% magnesium stearate mix homogeneously again.
Embodiments of the invention 2: be with thiamazole 5 grams, ethyl cellulose 5 grams, hydroxypropyl emthylcellulose (K
100M) 40 grams, water soluble starch 10 gram, lactose 10 grams, magnesium stearate 10 grams, that calcium carbonate 5 gram pulverize separately are crossed 100 mesh sieves is standby.1. ethyl cellulose is made into 20% solution for standby with ethanol.2. with thiamazole and hydroxypropyl emthylcellulose (K
100M) by equivalent incremental method mix homogeneously, with an amount of coating solution with it parcel after, again with magnesium stearate. wrap up with remaining coating solution behind the part calcium carbonate mix homogeneously, last and calcium carbonate, water soluble starch, lactose mix homogeneously, 20 mesh sieves are granulated, oven dry, 18 mesh sieve granulate, are pressed into the tablet that specification is 5mg after adding 2% magnesium stearate mix homogeneously again.
Embodiments of the invention 3: be with thiamazole 30 grams, ethyl cellulose 40 grams, hydroxypropyl emthylcellulose (K
100M) 70 grams, water soluble starch 30 gram, lactose 30 grams, magnesium stearate 30 grams, that calcium carbonate 20 gram pulverize separately are crossed 100 mesh sieves is standby.1. ethyl cellulose is made into 20% solution for standby with ethanol.2. with thiamazole and hydroxypropyl emthylcellulose (K
100M) by equivalent incremental method mix homogeneously, with an amount of coating solution with it parcel after, again with magnesium stearate. wrap up with remaining coating solution behind the part calcium carbonate mix homogeneously, last and calcium carbonate, water soluble starch, lactose mix homogeneously, 20 mesh sieves are granulated, oven dry, 18 mesh sieve granulate, are pressed into the tablet that specification is 30mg after adding 2% magnesium stearate mix homogeneously again.
Example 4: thiamazole drop pill
Thiamazole 10g, water soluble starch 5g, the broken mistake 100 mesh sieve mix homogeneously of lactose 5g are stand-by, press medicated powder: substrate 1: 2 is with after the fusion of substrate stearic acid, it is even to add medicament mixed, 70 ℃ of insulations add liquid paraffin, the collection drop pill with 60 droplets/minute, absorb liquid coolant with filter paper, get drop pill, the heavy 25mg of per 10 balls, day clothes 10 balls.
Example 5: thiamazole capsule
By recipe quantity thiamazole 10g, water soluble starch 10g, lactose 20g are pulverized 100 mesh sieves, filtered mix homogeneously; Add the beta-schardinger dextrin-of 20g, make 300 of capsules, each 1, day clothes 1 time.
Example 6: thiamazole granule
Press recipe quantity with thiamazole 10g, behind powder-beta-dextrin 20g parcel, adding water soluble starch 10g, lactose 20g mix homogeneously with the ethanol system soft material of concentration 90%, are made granule again, each 180mg, day clothes 1 time.
Example 7: thiamazole spray
Manufacture method is as follows: with thiamazole 10 grams, water soluble starch 20 grams, lactose 20 gram mix homogeneously are stand-by, add 10% tween 80 alcoholic solution 100ml, add 1,2-propylene glycol 100ml, mixing, ethanol is settled to 1000ml, the 50ml/ bottle is sub-packed in the aerosol pressure bottle, in every bottle, be pressed into dichlorodifluoromethane 5 grams behind the gland, make spray, daily 8-10ml.
Example 8: thiamazole slow releasing capsule
With thiamazole 10 grams, ethyl cellulose 10 grams, hydroxypropyl emthylcellulose (K
100M) 20 grams, water soluble starch 20 gram, lactose 10 grams, magnesium stearate 20 grams, that calcium carbonate 30 gram pulverize separately are crossed 100 mesh sieves is standby.1. ethyl cellulose is made into 20% solution for standby with ethanol.2. with thiamazole and hydroxypropyl emthylcellulose (K
100M) by equivalent incremental method mix homogeneously, with an amount of coating solution with it parcel after, wrap up with remaining coating solution again with behind the magnesium stearate mix homogeneously, last and calcium carbonate, water soluble starch, lactose mix homogeneously, 20 mesh sieves are granulated, are dried, 18 mesh sieve granulate, after adding 2% magnesium stearate mix homogeneously again, divide the capsule of packing into, that is, and usage and dosage: oral, every day 2 times, each 1.
Claims (10)
1, a kind of preparation that contains thiamazole is characterized in that: it is prepared into slow releasing tablet, drop pill, capsule, slow releasing capsule, granule, spray agent by thiamazole and adjuvant assembly.
2, according to the described preparation that contains thiamazole of claim 1, it is characterized in that: the thiamazole slow releasing tablet is formed by following material, and per thousand are by weight ratio: thiamazole 5-30 gram, ethyl cellulose 5-30 gram, hydroxypropyl emthylcellulose (K
100M) 20-70 restrains, water soluble starch 10-30 restrains, lactose 10-30 restrains, magnesium stearate 10-30 restrains, calcium carbonate 5-35 gram.
3, according to claim 1 or the 2 described preparations that contain thiamazole, it is characterized in that: per thousand slice prescriptions and the ratio of slow releasing tablet are: thiamazole 10 grams, ethyl cellulose 10 grams, hydroxypropyl emthylcellulose (K
100M) 20 grams, water soluble starch 20 gram, lactose 20 grams, magnesium stearate 20 grams, calcium carbonate 30 grams.
4, as claim 2 or the 3 described preparation methoies that contain the preparation of thiamazole, it is characterized in that: according to given ratio, with thiamazole, ethyl cellulose, hydroxypropyl emthylcellulose (K
100M), magnesium stearate, that calcium carbonate was pulverized 100 mesh sieves respectively was standby, it is standby as coating solution 1. ethyl cellulose to be made into 20% solution with ethanol, 2. with thiamazole and hydroxypropyl emthylcellulose (K
100M) by equivalent incremental method mix homogeneously, with an amount of coating solution with it parcel after, wrap up with remaining coating solution again with behind magnesium stearate, the part calcium carbonate mix homogeneously, mix homogeneously such as last and calcium carbonate, water soluble starch, lactose, 20 mesh sieves are granulated, oven dry, 18 mesh sieve granulate, add tabletting behind the 2% magnesium stearate mix homogeneously again.
5, according to the described preparation that contains thiamazole of claim 1, it is characterized in that: drop pill is formed by following material, by weight ratio: thiamazole 5-30 gram, water soluble starch 10-30 gram, lactose 10-30 gram; Substrate comprises a kind of of stearic acid or PEG6000 or PEG4000, and by medicated powder: substrate=1: 1-2 makes.
6, as claims 5 described preparation methoies that contain the preparation of thiamazole, it is characterized in that: being produced as follows of drop pill: thiamazole 5-30 gram, water soluble starch 10-30 gram, lactose 10-30 gram was pulverized 100 mesh sieves and is selected mix homogeneously stand-by; Press medicated powder: substrate=1: 1-2, with following substrate: after stearic acid or PEG6000 or the PEG4000 fusion, it is even to add medicament mixed, 60--70 ℃ of insulation dripped/minute added in liquid paraffin or the methyl-silicone oil with 40-70, collects drop pill, draw liquid coolant with filter paper, make drop pill.
7, according to the described preparation that contains thiamazole of claim 1, it is characterized in that: capsule is with thiamazole 5-30 gram, water soluble starch 10-30 gram, and lactose 10-30 restrains mix homogeneously, adds 10-60 gram beta-schardinger dextrin-, and filled capsules is made.
8, according to the described preparation that contains thiamazole of claim 1, it is characterized in that: granule is with thiamazole 5-30 gram, water soluble starch 10-30 gram, lactose 10-30 gram is made soft material with the ethanol of 40-90% concentration, makes granule with 20 mesh sieves, 60-80 ℃ of oven dry, granulate makes.
9, according to the described preparation that contains thiamazole of claim 1, it is characterized in that: spray is with thiamazole 5-30 gram, water soluble starch 10-30 gram, and lactose 10-30 gram mix homogeneously is stand-by, add 10-30% tween 80 alcoholic solution 10-100ml, add 1,2-propylene glycol 50-300ml, mixing, ethanol is settled to 40--1000ml, be sub-packed in the aerosol pressure bottle by 10-100ml (specification), in every bottle, be pressed into dichlorodifluoromethane 1-10 gram behind the gland, make.
10, according to the described preparation that contains thiamazole of claim 1, it is characterized in that: slow releasing capsule is with thiamazole 10 grams, ethyl cellulose 10 grams, hydroxypropyl emthylcellulose (K
100M) 20 grams, water soluble starch 20 gram, lactose 10 grams, magnesium stearate 20 grams, that calcium carbonate 30 gram pulverize separately are crossed 100 mesh sieves is standby, 1. ethyl cellulose is made into 20% solution for standby with ethanol, 2. with thiamazole and hydroxypropyl emthylcellulose (K
100M) by equivalent incremental method mix homogeneously, with an amount of coating solution with it parcel after, wrap up with remaining coating solution again with behind the magnesium stearate mix homogeneously, last and calcium carbonate, water soluble starch, lactose mix homogeneously, the granulation of 20 mesh sieves, oven dry, 18 mesh sieve granulate, after adding 2% magnesium stearate mix homogeneously again, divide the capsule of packing into, make.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410022207 CN1562004A (en) | 2004-03-30 | 2004-03-30 | Preparation containing methimazole and its preparing method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410022207 CN1562004A (en) | 2004-03-30 | 2004-03-30 | Preparation containing methimazole and its preparing method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1562004A true CN1562004A (en) | 2005-01-12 |
Family
ID=34479968
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200410022207 Pending CN1562004A (en) | 2004-03-30 | 2004-03-30 | Preparation containing methimazole and its preparing method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1562004A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100450480C (en) * | 2006-03-30 | 2009-01-14 | 华中科技大学 | Aquogel type thiamazole plaster preparation |
| CN104546760A (en) * | 2014-12-25 | 2015-04-29 | 海南卫康制药(潜山)有限公司 | Thiamazole composition freeze-drying tablet and preparation method thereof |
-
2004
- 2004-03-30 CN CN 200410022207 patent/CN1562004A/en active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100450480C (en) * | 2006-03-30 | 2009-01-14 | 华中科技大学 | Aquogel type thiamazole plaster preparation |
| CN104546760A (en) * | 2014-12-25 | 2015-04-29 | 海南卫康制药(潜山)有限公司 | Thiamazole composition freeze-drying tablet and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100475210C (en) | Modified release multiple-units dosage composition | |
| DE69919713T2 (en) | PHARMACEUTICAL PREPARATION WITH DELAYED ACTIVE INFUSION OF PHENYTOIN SODIUM | |
| EP2564847B1 (en) | Pharmaceutical composition for improving solubility of prasugrel and its preparation method | |
| KR100353304B1 (en) | Taste-masked microcapsule compositions and methods of manufacture | |
| DE69434640T2 (en) | Heterodisperse hydrogel systems for the sustained release of insoluble drugs | |
| CN108697803A (en) | The pharmaceutical composition of transmucosal administration | |
| US6558704B1 (en) | Process for preparing pellets containing up to 90 wt.% of a pharmaceutical active ingredient | |
| EP1390015A1 (en) | Taste-masking of highly water-soluble drugs | |
| CN101069675A (en) | A method of alleviating signs and symptons of spasticity | |
| US20170028007A1 (en) | Solid dispersion containing desmodium styracifolium (osb.) merr. flavonoids, method of preparing same, and use thereof | |
| CN103784411A (en) | Erlotinib hydrochloride medicinal composition and preparation method thereof | |
| EP0100061B1 (en) | Pharmaceutical combination composition and associated method | |
| KR20140019445A (en) | Compound chemical medicine acting on respiratory disease, preparation process and use thereof | |
| CN102451162A (en) | Olanzapine medicine absorbed through oral mucosa | |
| CN112294770A (en) | Isosorbide mononitrate compound preparation and application and preparation method thereof | |
| CN1562004A (en) | Preparation containing methimazole and its preparing method | |
| CN101416966B (en) | Medical composition capable of treating hypertension | |
| WO2002013829A1 (en) | Compositions containing an inhibitor of dihydrofolate reductase and a folate | |
| CN109394726B (en) | A kind of omeprazole sodium bicarbonate capsule and preparation method thereof | |
| CN103222966A (en) | Solid pharmaceutical composition containing Fingolimod hydrochloride and preparation method thereof | |
| CN101590038B (en) | Oral sustained release hypotensive composition | |
| CN100490806C (en) | Oral dispersion domperidone coutrolled-release gel and its preparing method | |
| CN101244068B (en) | Hemsleyadin sustained-release preparation | |
| CN108853044A (en) | A kind of Nifedipine sustained release tablets and preparation method thereof | |
| CN102579453A (en) | Compound preparation for treating gastric ulcer and preparation method of same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |